Listings current as of Tuesday, Oct. 13, 2026. View the Mobile Meeting Guide App for more details. 13 Sunday, Nov. 8 The Next Era in the Treatment of Hypertension 9:30–10:15 a.m. Learning Studio 3 SUPPORTER: Idorsia Pharmaceuticals Ltd. Factor XI Inhibition: The Next Era for Safer Stroke Prevention for Patients With Atrial Fibrillation 9:30–10:15 a.m. Learning Studio 4 SUPPORTER: Novartis Pharmaceutical Corporation Measuring Quality in the Evaluation, Surveillance and Treatment of Aortic Stenosis First Large-Scale Report From the American Heart Association Target: Aortic Stenosis Registry 9:45–10:15 a.m. CardioTalk 2 SUPPORTER: (HEART) Target: Aortic Stenosis TRYNGOLZA: Expand What’s Possible With Triglyceride Reduction in Severe Hypertriglyceridemia (sHTG; TGs ≥500 mg/dL) 11:15 a.m.–Noon Heart Theater 2 SUPPORTER: Ionis Pharmaceuticals Inc. Case-Based Approaches to Stroke Prevention 11:15 a.m.–Noon Learning Studio 1 SUPPORTER: Bristol Myers Squibb | Johnson & Johnson From Clinical Clues to Treatment With a TTR Stabilizer: Exploring ATTR-CM Through Patient Cases 11:15 a.m.–Noon Learning Studio 2 SUPPORTER: BridgeBio Pharma, Inc. Gene Therapy for the Failing Heart: Early Clinical Findings With Umiposgene Parvec (AB-1002) 11:15 a.m.–Noon Learning Studio 3 SUPPORTER: AskBio Inc. Bridging Evidence and Practice: Insights Into LDL-C Management With a Nonstatin Therapy 11:15 a.m.–Noon Learning Studio 4 SUPPORTER: Novartis Pharmaceutical Corporation Reviewing the Evidence for the Treatment of oHCM 11:15 a.m.–Noon Learning Studio 5 SUPPORTER: Cytokinetics, Inc. Beyond the Lungs: RSV and Cardiovascular Risk in Adults 11:30 a.m.-12:45 p.m. Industry Room N427D SUPPORTER: Pfizer Inc. Initiating Evidence‑Based Therapies for HFpEF and HFmrEF – A Multidisciplinary Approach 12:30–1:15 p.m. Heart Theater 1 SUPPORTER: (Heart) Implementation Science (QORA) Mounjaro® (tirzepatide) Product Theater 12:30–1:15 p.m. Learning Studio 1 SUPPORTER: Eli Lilly and Company Introduction to AMVUTTRA® (vutrisiran)” 12:30–1:15 p.m. Learning Studio 2 SUPPORTER: Alnylam Pharmaceuticals, Inc. An Oral Treatment Option for Adults With Hypercholesterolemia 12:30–1:15 p.m. Learning Studio 3 SUPPORTER: Merck & Co., Inc. Cardiovascular Outcomes in Patients at High CV Risk: Evidence From the Veaslius-CV Study 12:30–1:15 p.m. Learning Studio 4 SUPPORTER: Amgen Inc. 2026 INDUSTRY EVENTS Sunday, Nov. 8
RkJQdWJsaXNoZXIy MjI2NjI=